DNA methylation marker for early colorectal cancer and adenoma, method for detecting DNA methylation marker and application of DNA methylation marker

Abstract

The invention provides a DNA methylation marker for diagnosis, screening and risk prediction of early colorectal cancer and adenoma. The marker is characterized in that a CpG site in an NDRG4 gene is simultaneously methylated on at least two sites of the 38th site, the 47th site, the 50th site and the 52nd site in SEQ ID NO: 1. The invention also provides a method, a primer pair, a probe and a kit for detecting the DNA methylation marker. The method provided by the invention has good specificity and high sensitivity on early colorectal cancer and adenoma, is low in detection cost and simple to operate, and is beneficial to wide application of early colorectal cancer screening.

Description

technical field

[0001] The invention relates to the field of gene detection, in particular, the invention relates to a methylation marker of early colorectal cancer and adenoma, a detection method and application thereof. Background technique

[0002] In China, the incidence of colorectal cancer ranks fourth among all malignant tumors. Insufficient screening of colorectal cancer in China is the main reason for the low five-year survival rate of colorectal cancer in my country. The latest research shows that feces contain a small amount of nucleic acids derived from human intestinal epidermal exfoliated cells, and multi-target detection of these nucleic acids can effectively predict signs of malignant transformation. For example, multi-target detection of fecal DNA can be used to screen for intestinal cancer , although the sensitivity for high-grade adenomas is low. The fecal DNA multi-target detection technology was approved by the FDA for bowel cancer screening in 2014 an...

Images